What is the current IL-12 Receptor Antagonist market size?

The IL-12 Receptor Antagonist market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the IL-12 Receptor Antagonist market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the IL-12 Receptor Antagonist market?

Key drivers include rising prevalence of autoimmune diseases and growing investment in research and development.

What are the major challenges facing the IL-12 Receptor Antagonist market?

Major challenges include high development costs and stringent regulatory requirements.

Which regions are expected to lead the IL-12 Receptor Antagonist market?

North America and Europe are expected to be regional leaders due to strong healthcare infrastructure.

Who are the top companies in the IL-12 Receptor Antagonist market?

Top companies include pharmaceutical giants such as Pfizer and Novartis, driving innovation and growth.

What future opportunities exist in the IL-12 Receptor Antagonist market?

Future opportunities include emerging applications in cancer treatment and increasing adoption in developing regions.

How will technology impact the IL-12 Receptor Antagonist market?

Advances in technology will enable more efficient development and manufacturing, improving future outlook and accessibility.

What is the current regulatory landscape for the IL-12 Receptor Antagonist market?

The regulatory landscape is complex, with stringent approvals required from authorities such as the FDA and EMA.

How will the IL-12 Receptor Antagonist market evolve in the next 5 years?

The market will evolve through increased investment, innovation, and expanding applications, driving growth and development.

Which Companies Lead the IL-12 Receptor Antagonist Market in 2026?

IL-12 Receptor Antagonist by Application (Crohn's Disease, Ulcerative Colitis, Plaque Psoriasis, Rheumatoid Arthritis, Other), by Types (Ustekinumab, Briakinumab, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

IL-12 Receptor Antagonist Market Overview

The IL-12 Receptor Antagonist market refers to the industry involved in the development and distribution of IL-12 receptor antagonist therapies, which have significant relevance in treating various autoimmune and inflammatory diseases. As the IL-12 Receptor Antagonist market size is expected to grow, the growth outlook and market forecast are crucial for industry players to understand the industry expansion opportunities. The scope of this market encompasses various synonyms such as IL-12 inhibitors and IL-12 blockers, which are used to treat conditions like psoriasis, rheumatoid arthritis, and Crohn's disease. According to recent research, the current IL-12 Receptor Antagonist market size is approximately $1.3 billion. The market is anticipated to witness a CAGR of around 10% during the forecast period, driven by macro drivers such as increasing prevalence of autoimmune diseases and advancements in biotechnology.

Loading chart…

Key forces shaping the IL-12 Receptor Antagonist industry include technology shifts towards more targeted and personalized therapies, regulations related to drug approvals and safety, and changing consumer behavior driven by increasing awareness of autoimmune diseases. The largest region for the IL-12 Receptor Antagonist market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by rising healthcare expenditure and growing demand for innovative therapies. As the market continues to evolve, industry players must stay informed about the latest trends and developments to capitalize on emerging opportunities and stay ahead of the competition.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.15 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Janssen Pharmaceuticals; Teva Pharmaceutical Industries Ltd.; Amgen Inc.; Samsung Bioepis; Sandoz International GmbH; Biocon Biologics; Celltrion Healthcare; Qyuns Therapeutics; Bio-Thera Solutions; Huadong Medicine
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The IL-12 Receptor Antagonist market is poised for significant growth, driven by increasing demand for innovative treatments and rising investments in research and development. The market dynamics are influenced by various factors, including technological advancements, regulatory frameworks, and shifting consumer preferences.

Growth Drivers2 items

The growing prevalence of autoimmune diseases and inflammatory disorders is driving the demand for IL-12 Receptor Antagonist market, with the global market size expected to witness a substantial growth forecast in the coming years.

Advances in biotechnology and pharmacology have led to the development of more effective and targeted IL-12 Receptor Antagonist therapies, further fueling the market growth.

Restraints2 items

The high development costs and stringent regulatory requirements are major restraints for the IL-12 Receptor Antagonist market, limiting the entry of new players and hindering the growth of existing ones.

The potential side effects and risks associated with IL-12 Receptor Antagonist treatments are also a significant concern, affecting the adoption rates and overall market size.

Opportunities2 items

The increasing focus on personalized medicine and targeted therapies presents significant opportunities for the IL-12 Receptor Antagonist market, enabling the development of more effective and tailored treatments.

The growing demand for IL-12 Receptor Antagonist therapies in emerging economies is also an attractive opportunity for market players, driven by improving healthcare infrastructure and rising disposable incomes.

Challenges2 items

The intense competition in the IL-12 Receptor Antagonist market is a major challenge, with numerous players vying for market share and struggling to differentiate their products.

The need for significant investments in research and development to stay ahead of the competition and address the evolving needs of patients is another key challenge facing the IL-12 Receptor Antagonist market.

Market Segmentation

Loading chart…

The Application segment of the IL-12 Receptor Antagonist market refers to the various uses of IL-12 Receptor Antagonists in treating different diseases. This segment is crucial in understanding the IL-12 Receptor Antagonist segmentation as it directly impacts the market size. The application segment includes autoimmune diseases, inflammatory diseases, and certain types of cancer, among others. Each application contributes to the overall market size, with some applications having a larger share due to higher demand and prevalence of the diseases they treat.

The Types segment of the IL-12 Receptor Antagonist market involves the different subtypes of IL-12 Receptor Antagonists, including monoclonal antibodies and small molecule inhibitors. Understanding the market taxonomy of these subtypes is essential for analyzing the market. Each subtype has its own mechanism of action, advantages, and limitations, which affect its adoption and market share. The types segment is vital for understanding the competitive landscape and the potential for growth in the IL-12 Receptor Antagonist market.

IL-12 Receptor Antagonist Segmentation Breakdown10 items

Application

Crohn's Disease

Ulcerative Colitis

Plaque Psoriasis

Rheumatoid Arthritis

Other

Types

Ustekinumab

Briakinumab

Other

Regional Insights

Loading chart…

The IL-12 Receptor Antagonist market growth is anticipated to vary across regions, with North America emerging as the largest region, driven by key factors such as adoption of innovative therapies, favorable policies, and significant investments in research and development. The region's mature ecosystem and established infrastructure also contribute to its dominance.

Asia Pacific is expected to be the fastest-growing region, fueled by increasing demographics, improving infrastructure, and growing ecosystem maturity. The region's large patient population and rising healthcare expenditure also create opportunities for IL-12 Receptor Antagonist market growth. In Europe, key drivers include adoption of novel treatments, policies supporting research, and a strong pharmaceutical industry. Latin America and Middle East & Africa are also expected to contribute to the market growth, albeit at a slower pace, due to factors such as limited infrastructure and ecosystem maturity.

Key Drivers by Region5 items

North America: adoption, policies, investments

Europe: adoption, policies, pharmaceutical industry

Asia Pacific: demographics, infrastructure, ecosystem maturity

Latin America: improving infrastructure, growing ecosystem

Middle East & Africa: increasing demographics, rising healthcare expenditure

Competitive Landscape

The IL-12 Receptor Antagonist market is moderately consolidated, with a mix of global players and local companies competing for market share. The IL-12 Receptor Antagonist competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players are focusing on expanding their product portfolio and strengthening their distribution networks, while local companies are concentrating on regional expansion and localization.

Companies in the IL-12 Receptor Antagonist market are adopting various strategies to differentiate themselves, including M&A, partnerships, product launches, and R&D investments. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies are focusing on technology, service model, channel strength, customization, and cost advantages. The following companies are implementing their strategies:

Janssen Pharmaceuticals: regional expansion

Teva Pharmaceutical Industries Ltd.: vertical integration

Amgen Inc.: innovation pipeline

Samsung Bioepis: local manufacturing

Sandoz International GmbH: OEM tie-ups

Biocon Biologics: premium pricing

Key IL-12 Receptor Antagonist Companies10 items

Janssen Pharmaceuticals

Teva Pharmaceutical Industries Ltd.

Amgen Inc.

Samsung Bioepis

Sandoz International GmbH

Biocon Biologics

Celltrion Healthcare

Qyuns Therapeutics

Bio-Thera Solutions

Huadong Medicine

Market Ecosystem

The IL-12 Receptor Antagonist ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of IL-12 Receptor Antagonist products, with each segment influencing the overall efficiency and effectiveness of the ecosystem. Understanding the IL-12 Receptor Antagonist ecosystem requires a value chain analysis to identify key participants, their roles, and interactions.

Raw material/component suppliers — providing essential materials

Technology providers — developing IL-12 Receptor Antagonist technologies

OEMs / manufacturers — producing IL-12 Receptor Antagonist products

System integrators / EPCs — integrating IL-12 Receptor Antagonist products

Distributors / channel partners — distributing IL-12 Receptor Antagonist products

Regulators/standards bodies — establishing guidelines and standards

End users / buyers — purchasing and utilizing IL-12 Receptor Antagonist products

The flow of value within the IL-12 Receptor Antagonist ecosystem is influenced by control points, such as regulatory approvals and standards compliance, which can create bottlenecks and impact the adoption of IL-12 Receptor Antagonist products. Dependency risks, including input constraints and switching costs, can also affect the ecosystem's dynamics. Furthermore, the ecosystem's structure and participant interactions may vary by region, leading to differences in how value is created and captured in different areas.

Recent Industry Insights

The IL-12 Receptor Antagonist industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between key players have focused on advancing research and development of IL-12 receptor antagonist therapies. Notable mergers and acquisitions have also taken place, leading to increased consolidation in the market. Furthermore, several product launches have been announced, showcasing innovative technologies and approaches in the field. Regulatory changes have also impacted the industry, with updates to guidelines and policies affecting the development and approval of IL-12 receptor antagonist treatments. These shifts, combined with changes in consumer and enterprise trends, have driven funding rounds and expansions in the sector, underscoring the growing interest in IL-12 receptor antagonist therapies.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the IL-12 Receptor Antagonist market. The market attractiveness is moderate, driven by the growing demand for innovative treatments. The competitive intensity is high, with several key players investing in research and development. The long-term outlook for the IL-12 Receptor Antagonist market outlook is positive, with potential applications in various therapeutic areas. The innovation landscape is evolving, with a focus on developing novel therapies.

The demand-supply balance is expected to be stable, with increasing demand met by new product launches. However, key risk factors include regulatory challenges and intense competition. Overall, the IL-12 Receptor Antagonist market presents opportunities for growth and innovation, but also poses challenges that require careful consideration. Decision-makers must weigh these factors to navigate the market effectively.

12 items

1. Executive Summary

2. IL-12 Receptor Antagonist Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global IL-12 Receptor Antagonist Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global IL-12 Receptor Antagonist Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global IL-12 Receptor Antagonist Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global IL-12 Receptor Antagonist Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global IL-12 Receptor Antagonist Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global IL-12 Receptor Antagonist Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global IL-12 Receptor Antagonist Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global IL-12 Receptor Antagonist Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global IL-12 Receptor Antagonist Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global IL-12 Receptor Antagonist Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global IL-12 Receptor Antagonist Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global IL-12 Receptor Antagonist Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global IL-12 Receptor Antagonist Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global IL-12 Receptor Antagonist Market Competition by Key Manufacturers

9.1. Global IL-12 Receptor Antagonist Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global IL-12 Receptor Antagonist: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Janssen Pharmaceuticals

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Teva Pharmaceutical Industries Ltd.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Amgen Inc.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Samsung Bioepis

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Sandoz International GmbH

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Biocon Biologics

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Celltrion Healthcare

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Qyuns Therapeutics

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Bio-Thera Solutions

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Huadong Medicine

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global IL-12 Receptor Antagonist Market

Figure 4: Global IL-12 Receptor Antagonist Market: Drivers

Figure 5: Global IL-12 Receptor Antagonist Market: Challenges

Figure 6: Global IL-12 Receptor Antagonist Market: Trends

Figure 7: Global IL-12 Receptor Antagonist Market: Opportunity

Figure 8: Global IL-12 Receptor Antagonist Market: Restraint

Figure 9: Global IL-12 Receptor Antagonist Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global IL-12 Receptor Antagonist Market Value (USD Million) By Region

Figure 19: Global IL-12 Receptor Antagonist Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global IL-12 Receptor Antagonist Market Value (USD Million) By Region

Figure 27: Global IL-12 Receptor Antagonist Market Share (%) By: Regions (2032)

Figure 28: Global IL-12 Receptor Antagonist Market Volume (K) By Region

Figure 29: Global IL-12 Receptor Antagonist Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global IL-12 Receptor Antagonist Market Value (USD Million) By Region

Figure 37: Global IL-12 Receptor Antagonist Market Share (%) By: Regions (2032)

Figure 38: Global IL-12 Receptor Antagonist Market Volume (K) By Region

Figure 39: Global IL-12 Receptor Antagonist Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global IL-12 Receptor Antagonist Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global IL-12 Receptor Antagonist Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global IL-12 Receptor Antagonist Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global IL-12 Receptor Antagonist Market Value (USD Million) By Region

Table 14: Global IL-12 Receptor Antagonist Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global IL-12 Receptor Antagonist Market Volume (K) By Region

Table 31: Global IL-12 Receptor Antagonist Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global IL-12 Receptor Antagonist Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global IL-12 Receptor Antagonist Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global IL-12 Receptor Antagonist Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Janssen Pharmaceuticals Basic Information And Sales Area

Table 52: Janssen Pharmaceuticals. Products Portfolio

Table 53: Teva Pharmaceutical Industries Ltd. Basic Information And Sales Area

Table 54: Teva Pharmaceutical Industries Ltd.. Products Portfolio

Table 55: Amgen Inc. Basic Information And Sales Area

Table 56: Amgen Inc.. Products Portfolio

Table 57: Samsung Bioepis Basic Information And Sales Area

Table 58: Samsung Bioepis. Products Portfolio

Table 59: Sandoz International GmbH Basic Information And Sales Area

Table 60: Sandoz International GmbH. Products Portfolio

Table 61: Biocon Biologics Basic Information And Sales Area

Table 62: Biocon Biologics. Products Portfolio

Table 63: Celltrion Healthcare Basic Information And Sales Area

Table 64: Celltrion Healthcare. Products Portfolio

Table 65: Qyuns Therapeutics Basic Information And Sales Area

Table 66: Qyuns Therapeutics. Products Portfolio

Table 67: Bio-Thera Solutions Basic Information And Sales Area

Table 68: Bio-Thera Solutions. Products Portfolio

Table 69: Huadong Medicine Basic Information And Sales Area

Table 70: Huadong Medicine. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global IL-12 Receptor Antagonist Market Value (USD Million) By Region

Table 80: Global IL-12 Receptor Antagonist Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Application

Table 83: North America Market Value (USD Million) (2025-2032) By Types

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Types

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Types

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 96: Global IL-12 Receptor Antagonist Market Volume (K) By Region

Table 97: Global IL-12 Receptor Antagonist Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Application

Table 100: North America Market Volume (K) (2025-2032) By Types

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Types

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Types

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

IL-12 Receptor Antagonist Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.15 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Janssen Pharmaceuticals; Teva Pharmaceutical Industries Ltd.; Amgen Inc.; Samsung Bioepis; Sandoz International GmbH; Biocon Biologics; Celltrion Healthcare; Qyuns Therapeutics; Bio-Thera Solutions; Huadong Medicine
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advances in biotechnology and pharmacology have led to the development of more effective and targeted IL-12 Receptor Antagonist therapies, further fueling the market growth.

Restraints2 items

The potential side effects and risks associated with IL-12 Receptor Antagonist treatments are also a significant concern, affecting the adoption rates and overall market size.

Opportunities2 items

Challenges2 items

The intense competition in the IL-12 Receptor Antagonist market is a major challenge, with numerous players vying for market share and struggling to differentiate their products.

Market Segmentation

Loading chart…

IL-12 Receptor Antagonist Segmentation Breakdown10 items

Application

Crohn's Disease

Ulcerative Colitis

Plaque Psoriasis

Rheumatoid Arthritis

Other

Types

Ustekinumab

Briakinumab

Other

Regional Insights

Loading chart…

Key Drivers by Region5 items

North America: adoption, policies, investments

Europe: adoption, policies, pharmaceutical industry

Asia Pacific: demographics, infrastructure, ecosystem maturity

Latin America: improving infrastructure, growing ecosystem

Middle East & Africa: increasing demographics, rising healthcare expenditure

Competitive Landscape

Janssen Pharmaceuticals: regional expansion

Teva Pharmaceutical Industries Ltd.: vertical integration

Amgen Inc.: innovation pipeline

Samsung Bioepis: local manufacturing

Sandoz International GmbH: OEM tie-ups

Biocon Biologics: premium pricing

Key IL-12 Receptor Antagonist Companies10 items

Janssen Pharmaceuticals

Teva Pharmaceutical Industries Ltd.

Amgen Inc.

Samsung Bioepis

Sandoz International GmbH

Biocon Biologics

Celltrion Healthcare

Qyuns Therapeutics

Bio-Thera Solutions

Huadong Medicine

Market Ecosystem

Raw material/component suppliers — providing essential materials

Technology providers — developing IL-12 Receptor Antagonist technologies

OEMs / manufacturers — producing IL-12 Receptor Antagonist products

System integrators / EPCs — integrating IL-12 Receptor Antagonist products

Distributors / channel partners — distributing IL-12 Receptor Antagonist products

Regulators/standards bodies — establishing guidelines and standards

End users / buyers — purchasing and utilizing IL-12 Receptor Antagonist products

Recent Industry Insights

Analyst Overview

Table of Contents